The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2025 TheOutpost.AI All rights reserved
Curated by THEOUTPOST
On Tue, 7 Jan, 12:01 AM UTC
2 Sources
[1]
UPDATE - Basecamp Research Appoints John Finn, Ph.D., as CSO, Expands Internationally with U.S. Lab and Offices, and Builds One of Europe's Largest Industrial Supercomputers with NVIDIA Accelerated Computing
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter Finn, an industry leader in the field of cell and gene therapy, will lead company's efforts to advance groundbreaking approaches to programmable genetic medicines Office and lab in Kendall Square (Cambridge, Mass.) to focus on expanding Company's network of best-in-class therapeutic partnerships New, purpose-built NVIDIA accelerated computing cluster - one of the most advanced industrial compute infrastructures in Europe - matches the company's unique data advantage and fuels the design of completely new biological systems LONDON and CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Basecamp Research, an AI company dedicated to solving the most pressing challenges in life sciences, today announced that John Finn, Ph.D., will join as Chief Scientific Officer (CSO) as the company establishes a Boston lab and office to accelerate its pursuit of programmable genetic medicines. "John is a globally-recognised leader in cell and gene therapy who has spent more than 25 years pursuing extremely complex scientific and technological challenges," said Glen Gowers, Ph.D., Basecamp Research co-founder and CEO. "With John's experience, our huge data advantage and our pioneering new class of foundation models, Basecamp Research is positioned to go beyond known biology and achieve groundbreaking advances that improve human health." Finn most recently served as Chief Scientific Officer of Tome Biosciences, where he pioneered new methods of large gene insertion for therapeutic applications. He also held senior leadership positions at Codiak BioSciences and Intellia Therapeutics. He has dedicated his career to advancing the field of gene and cell therapy through innovations in both delivery and editing technologies. He received his Ph.D. in Biochemistry and Molecular Biology from The University of British Columbia and did post-doctoral research at McMaster University and the Children's Hospital of Philadelphia. "I was drawn to Basecamp Research because of the incredible opportunity to develop the next generation of programmable genetic medicines and address challenges facing the field today," Finn said. "Basecamp Research's advantage of a vast and unique dataset, combined with its next generation of AI models, really complements my experience in genetic medicines. I'm excited to see how we can leverage these synergies to continue my life's mission of advancing scientific discoveries that can lead to new treatments for patients in need." Expanded Team and Footprint in Boston's Kendall Square Finn will join a growing team, including the company's Chief Commercial Officer Anupama Hoey, at the company's new lab and office in Kendall Square, a world-renowned biotechnology innovation district in Cambridge, Mass. These facilities add to the company's ability to validate sophisticated biological systems designed by its foundation models. Also joining the Cambridge office alongside Finn is Konstantinos Andrikopoulos as Senior Vice President for Intellectual Property. Andrikopoulos brings 27 years of pharma IP experience, including senior positions at Biogen, Tome Biosciences and Vertex Pharmaceuticals. Pairing Data with Compute to Enable Scaling of AI Foundation Models To design these programmable medicines, Basecamp Research is building new classes of foundational AI models that are capable of tackling increasingly complex biological design challenges. The Company's recent $60 million Series B round has already fueled a rapid expansion of their proprietary foundational dataset, allowing it to collect 10 times more data in the last three months than was collected in the previous three years. Alongside this expansion of data comes a corresponding expansion of compute power. Basecamp Research has built one of the most advanced industrial compute infrastructures in Europe. The cluster, comprising NVIDIA H200 GPUs, is one of the first to be purpose-built for training long-context AI foundation models. Basecamp Research needs this long context capability to work with the ever-increasing high-quality genomic data it is collecting around the world. Basecamp Research has built one of the world's largest commercial biodiscovery program, spanning more than 120 locations in over 25 countries, to give its AI models a complete understanding of the true breadth and complexity of biology. The Company uses this combination of proprietary data and powerful models in a wide range of partnerships, including a multi-year collaboration with the laboratory of Dr. David R. Liu at the Broad Institute of MIT and Harvard and partnerships with three of the top 10 pharmaceutical companies. About Basecamp Research Basecamp Research is solving the most pressing challenges in the life sciences by exploring beyond known biology. We build foundational AI models on top of the world's largest, ethically-sourced database of biological information to give AI the most complete understanding of biology ever. This allows us to design more complex biological systems than anyone else with performance improving dramatically as AI sees more diversity and context. Basecamp Research collaborates with biopharma companies and academic research institutions to design novel protein sequences and biological systems that can transform therapeutic research and development. Our team of explorers, scientists and policy experts proudly work with more than 100 biodiversity partners across the globe, allowing us to deliver breakthroughs that can have a profound impact on healthcare and the lives of patients. Basecamp Research was named one of Bloomberg's "Top 25 UK Startups to Watch" for 2024. For more information, visit basecamp-research.com. Adam Silverstein SCIENT PR adam@scientpr.com Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/08653abb-fe4a-4b97-a0a5-0d23cb388440 https://www.globenewswire.com/NewsRoom/AttachmentNg/2be838aa-4ea2-49bc-8ab3-9698c86a6c0b Market News and Data brought to you by Benzinga APIs
[2]
Basecamp Research Appoints John Finn, Ph.D., as CSO, Expands Internationally with U.S. Lab and Offices, and Builds One of Europe's Largest Industrial Supercomputers with NVIDIA Accelerated Computing
Finn, an industry leader in the field of cell and gene therapy, will lead company's efforts to advance groundbreaking approaches to programmable genetic medicines Office and lab in Kendall Square (Cambridge, Mass.) to focus on expanding Company's network of best-in-class therapeutic partnerships New, purpose-built NVIDIA accelerated computing cluster - one of the most advanced industrial compute infrastructures in Europe - matches the company's unique data advantage and fuels the design of completely new biological systems LONDON and CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Basecamp Research, an AI company dedicated to solving the most pressing challenges in life sciences, today announced that John Finn, Ph.D., will join as Chief Scientific Officer (CSO) as the company establishes a Boston lab and office to accelerate its pursuit of programmable genetic medicines. "John is a globally-recognised leader in cell and gene therapy who has spent more than 25 years pursuing extremely complex scientific and technological challenges," said Glen Gowers, Ph.D., Basecamp Research co-founder and CEO. "With John's experience, our huge data advantage and our pioneering new class of foundation models, Basecamp Research is positioned to go beyond known biology and achieve groundbreaking advances that improve human health." Finn most recently served as Chief Scientific Officer of Tome Biosciences, where he pioneered new methods of large gene insertion for therapeutic applications. He also held senior leadership positions at Codiak BioSciences and Intellia Therapeutics. He has dedicated his career to advancing the field of gene and cell therapy through innovations in both delivery and editing technologies. He received his Ph.D. in Biochemistry and Molecular Biology from The University of British Columbia and did post-doctoral research at McMaster University and the Children's Hospital of Philadelphia. "I was drawn to Basecamp Research because of the incredible opportunity to develop the next generation of programmable genetic medicines and address challenges facing the field today," Finn said. "Basecamp Research's advantage of a vast and unique dataset, combined with its next generation of AI models, really complements my experience in genetic medicines. I'm excited to see how we can leverage these synergies to continue my life's mission of advancing scientific discoveries that can lead to new treatments for patients in need." Expanded Team and Footprint in Boston's Kendall Square Finn will join a growing team, including the company's Chief Commercial Officer Annupama Hoey, at the company's new lab and office in Kendall Square, a world-renowned biotechnology innovation district in Cambridge, Mass. These facilities add to the company's ability to validate sophisticated biological systems designed by its foundation models. Also joining the Cambridge office alongside Finn is Konstantinos Andrikopoulos as Senior Vice President for Intellectual Property. Andrikopoulos brings 27 years of pharma IP experience, including senior positions at Biogen, Tome Biosciences and Vertex Pharmaceuticals. Pairing Data with Compute to Enable Scaling of AI Foundation Models To design these programmable medicines, Basecamp Research is building new classes of foundational AI models that are capable of tackling increasingly complex biological design challenges. The Company's recent $60 million Series B round has already fueled a rapid expansion of their proprietary foundational dataset, allowing it to collect 10 times more data in the last three months than was collected in the previous three years. Alongside this expansion of data comes a corresponding expansion of compute power. Basecamp Research has built one of the most advanced industrial compute infrastructures in Europe. The cluster, comprising NVIDIA H200 GPUs, is one of the first to be purpose-built for training long-context AI foundation models. Basecamp Research needs this long context capability to work with the ever-increasing high-quality genomic data it is collecting around the world. Basecamp Research has built one of the world's largest commercial biodiscovery program, spanning more than 120 locations in over 25 countries, to give its AI models a complete understanding of the true breadth and complexity of biology. The Company uses this combination of proprietary data and powerful models in a wide range of partnerships, including a multi-year collaboration with the laboratory of Dr. David R. Liu at the Broad Institute of MIT and Harvard and partnerships with three of the top 10 pharmaceutical companies. About Basecamp Research Basecamp Research is solving the most pressing challenges in the life sciences by exploring beyond known biology. We build foundational AI models on top of the world's largest, ethically-sourced database of biological information to give AI the most complete understanding of biology ever. This allows us to design more complex biological systems than anyone else with performance improving dramatically as AI sees more diversity and context. Basecamp Research collaborates with biopharma companies and academic research institutions to design novel protein sequences and biological systems that can transform therapeutic research and development. Our team of explorers, scientists and policy experts proudly work with more than 100 biodiversity partners across the globe, allowing us to deliver breakthroughs that can have a profound impact on healthcare and the lives of patients. Basecamp Research was named one of Bloomberg's "Top 25 UK Startups to Watch" for 2024. For more information, visit basecamp-research.com. Adam Silverstein SCIENT PR adam@scientpr.com Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/08653abb-fe4a-4b97-a0a5-0d23cb388440 https://www.globenewswire.com/NewsRoom/AttachmentNg/2be838aa-4ea2-49bc-8ab3-9698c86a6c0b Market News and Data brought to you by Benzinga APIs
Share
Share
Copy Link
Basecamp Research appoints John Finn as CSO, opens a U.S. lab, and builds one of Europe's largest industrial supercomputers to accelerate AI-driven programmable genetic medicine development.
Basecamp Research, an AI company focused on solving pressing challenges in life sciences, has announced significant developments in its leadership and infrastructure. The company has appointed John Finn, Ph.D., as its new Chief Scientific Officer (CSO) and is expanding its operations internationally 12.
Dr. John Finn, a renowned leader in cell and gene therapy with over 25 years of experience, joins Basecamp Research as CSO. His appointment is aimed at advancing the company's efforts in programmable genetic medicines. Finn's extensive background includes serving as CSO at Tome Biosciences and holding senior positions at Codiak BioSciences and Intellia Therapeutics 12.
Basecamp Research is establishing a new lab and office in Kendall Square, Cambridge, Massachusetts, a hub for biotechnology innovation. This expansion aims to accelerate the company's pursuit of programmable genetic medicines and expand its network of therapeutic partnerships 12.
In a significant technological advancement, Basecamp Research has built one of Europe's largest industrial supercomputers. This NVIDIA accelerated computing cluster, featuring H200 GPUs, is specifically designed for training long-context AI foundation models. This infrastructure is crucial for processing the company's expanding genomic dataset 12.
Basecamp Research is developing new classes of foundational AI models capable of tackling complex biological design challenges. The company's recent $60 million Series B funding has fueled a rapid expansion of its proprietary dataset, allowing it to collect ten times more data in the last three months than in the previous three years 12.
The company has established one of the world's largest commercial biodiscovery programs, spanning over 120 locations in more than 25 countries. This extensive program aims to provide AI models with a comprehensive understanding of biological diversity and complexity 12.
Basecamp Research is leveraging its proprietary data and AI models in various partnerships, including a multi-year collaboration with Dr. David R. Liu's laboratory at the Broad Institute of MIT and Harvard. The company also has partnerships with three of the top 10 pharmaceutical companies 12.
With these developments, Basecamp Research is positioning itself at the forefront of AI-driven life sciences research. The company aims to go beyond known biology and achieve groundbreaking advances in human health, particularly in the field of programmable genetic medicines 12.
Reference
Basecamp Research, a London-based startup, has secured $60 million in Series B funding to develop AI models for life sciences, aiming to create a 'ChatGPT for nature' by collecting and analyzing vast amounts of biological data.
4 Sources
4 Sources
NVIDIA introduces the open-source BioNeMo Framework, a suite of accelerated computing tools designed to scale AI models for biomolecular research, aiming to revolutionize drug discovery and molecule design in the pharmaceutical and scientific industries.
2 Sources
2 Sources
Diag-Nose.io, a biotech startup, has raised $2 million in seed funding to develop an AI-powered precision medicine system for respiratory diseases. The company is expanding operations and plans to launch clinical studies across the US in 2025.
3 Sources
3 Sources
Shift Bioscience, a biotech company using AI-powered virtual cells to combat age-related diseases, establishes new facilities in Toronto, Canada. This expansion aims to leverage the region's AI talent pool and advance their platform for discovering rejuvenation gene targets.
2 Sources
2 Sources
Renovaro Inc.'s subsidiary, RenovaroCube, secures Eurostars funding for its Lumina project, an AI-powered platform for lung cancer detection. The company also appoints Maurice van Tilburg as CEO of the subsidiary to lead its development and commercialization efforts.
4 Sources
4 Sources
